News | Stents | November 10, 2017

Cordis Showcases Comprehensive Interventional Cardiology Portfolio with Coronary Stents at TCT 2017

Portfolio now includes Medinol’s Tryton Side Branch Stent and NIRxcell bare metal stent

November 10, 2017 — Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now includes two coronary stents — the Tryton Side Branch Stent and Medinol’s NIRxcell, a cobalt-chromium bare metal stent (BMS). Cordis’ cardiology products were on display during the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.

The recent Cardinal Health agreement with Israel-based Medinol gives Cordis exclusive rights to sell Medinol’s coronary stent portfolio in the United States. Cordis is now selling Medinol’s NIRxcell BMS and, upon Medinol receiving U.S. Food and Drug Administration (FDA) approval, Cordis will also be the exclusive distributor of the EluNIR drug-eluting stent (DES). The EluNIR DES is currently an investigational device and not approved for commercial use in the U.S.

Medinol’s NIRxcell Bare-Metal Stent and EluNIR Drug-Eluting Stent are supported by a large body of clinical data, according to the company. The NIRxcell BMS has been tested on more than 1,000 patients and found highly effective in numerous clinical trials. Data from BIONICS, a global pivotal study of 1,919 patients from 76 sites in 8 countries, was submitted to the FDA to support U.S. regulatory approval of the EluNIR DES for the treatment of patients with narrowing or blockages to their coronary arteries. The EluNIR DES is currently an investigational device and not approved for commercial use in the U.S. Medinol recently received CE-mark and other regulatory clearances in Europe for the EluNIR stent.

The Tryton Side Branch Stent, the first dedicated bifurcation device to receive regulatory approval in the U.S., is approved for the treatment of de novo coronary bifurcation lesions involving large side branches (appropriate for a ≥2.5mm stent). The device is built using proprietary Tri-Zone technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt-chromium stent is deployed in the side branch artery using a standard, single-wire, balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

For more information: www.cordis.com

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...